For investment professionals only

In Walter Scott's latest quarterly podcast, Investment Manager Paul Loudon considers current goings-on in China and why, in his view, the picture there is not all doom and gloom. He also shares insights from recent debates and the team’s latest travels before fellow Investment Manager Lindsay Scott joins him to talk about the ground-breaking, hugely topical and often controversial obesity drugs that have been developed by Novo Nordisk and Eli Lilly.

The podcast is intended for investment professionals only and should not be construed as investment advice or a recommendation. Any stock examples discussed are given in the context of the theme being explored, and the views expressed are those of the presenters at the time of the recording.